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Erectile Dysfunction Is Common among Patients with
Gout
Naomi Schlesinger, Diane C. Radvanski, Jerry Q. Cheng, and John B. Kostis
ABSTRACT. Objective. To determine whether men with gout may have an increased prevalence of erectile
dysfunction (ED) as compared with men without gout.
Methods. In this cross-sectional study, men aged 18–89 presenting to the rheumatology clinic between
August 26, 2010,  and May 13, 2013, were asked to participate. The presence of ED was determined
by the Sexual Health Inventory in Men (SHIM). SHIM classifies ED into 1 of 5 categories: absent
(22–25), mild (17–21), mild to moderate (12–16), moderate (8–11), and severe (1–7). Patient’s history,
physical examination, and recent laboratory studies were reviewed as well. Descriptive statistics and
subgroup analyses were used to summarize the data.
Results. Of the 201 men surveyed, 83 had gout (control, n = 118). A significantly greater proportion
of patients with gout (63, 76%) had ED versus patients without gout (60, 51%, p = 0.0003). A signifi -
cantly greater proportion of patients with gout (22, 26%) had severe ED versus patients without gout
(17, 15%, p = 0.04). Patients with gout had an average SHIM score of 14.4 versus 18.48 in patients
without gout (p < 0.0001). There was a statistically significant association between gout and ED. The
association remained significant after adjustment for age, hypertension, diabetes, and obesity.
Conclusion. ED is present in most men with gout and is frequently severe. We propose that patients
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Erectile dysfunction (ED) is common in the general
population, affecting about 50% of 40- to 70-year-old men1.
The National Institutes of Health Consensus Development
statement defined ED as the “inability of the male to attain
and maintain erection of the penis sufficient to permit satis-
factory sexual intercourse”2. The likelihood of ED increases
with age, but is not an inevitable consequence of aging2.
The importance of cardiovascular (CV) disease (CVD) as
an underlying cause of ED is well established3,4. This is not
surprising because CVD and ED share mutual risk factors
such as diabetes mellitus (DM), hypertension (HTN),
advanced age, hypercholesterolemia, obesity, metabolic
syndrome, certain medications such as antidepressants, and
tobacco abuse1,3,5,6.
New evidence shows that hyperuricemia and inflam-
mation may be independent risk factors for ED in addition to
the established ones. In a recent study by Solak, et al7, of 312
men who underwent an exercise stress test because of chest
pain, each 1 mg/dl increase in serum urate (SU) was
associated with a 31% increased risk of ED. Compared with
patients in the first quartile of SU level, those in the fourth
quartile had a 2.6 times increased risk of ED. However, in an
adjusted analysis for traditional CV risk factors, the
relationship with SU was no longer significant. Another
recent study, by Salem, et al8, evaluated SU level and the
distribution of potential ED risk factors in 251 men with
newly diagnosed ED versus 252 age-matched controls
without ED. A significant difference was found between
mean SU levels in men with ED (6.12 mg/dl) versus men
without ED (4.97 mg/dl). The men in the highest tertile of
SU level had a 6-fold increased risk of ED compared with
men in the lowest tertile. Each 1 mg/dl increase in SU level
was associated with a 2-fold increased risk of ED.
Inflammation, too, plays an important role in ED9,10. Low
levels of interleukin 6 (IL-6) and fibrinogen exclude the
presence of ED in patients with coronary artery disease
(CAD) or with unfavorable risk factors9. It has been shown
that plasma levels of high-sensitivity C-reactive protein
(CRP) were significantly higher in patients with ED
compared with patients without ED11,12.
We did not find any publications on PubMed in the
English medical literature investigating whether gout is
associated with ED. We hypothesized that men with gout may
have an increased prevalence of ED as compared with men
without gout.
MATERIALS AND METHODS 
Our study was a cross-sectional study of men aged 18–89 years presenting
to the Rheumatology clinic with any form of arthritis between August 26,
2010, and May 13, 2013. The study protocol was approved by the University
of Medicine and Dentistry of New Jersey’s institutional review board, and
all the participants signed informed consent forms before recruitment.
Included patients were asked to complete the Sexual Health Inventory
in Men (SHIM) questionnaire. The SHIM sample was dependent on the
availability of the authors. Patients attending clinic more frequently were
more likely to be included. SHIM is an established, valid, and reliable
questionnaire for determining the presence and severity of ED. SHIM has
been shown to have high internal consistency (0.90), test-retest repeatability
(r = 0.84), and construct (concurrent, convergent and discriminant)
validity13. SHIM is a 5-item erectile function domain also known as the
International Index of Erectile Function (IIEF) questionnaire13. SHIM
consists of 5 questions. For each of the 5, the subject indicates an answer
between 0 and 5. The prevalence of ED is generally based on a SHIM score
of 21 or less. SHIM classifies ED into 1 of 5 categories: absent (22–25),
mild (17–21), mild to moderate (12–16), moderate (8–11), and severe (1–7).
Gout diagnosis was reassessed retrospectively by investigating the
medical reports. Authors doing chart review were not aware of the results
of the SHIM. We accepted the diagnosis of gout if there was documentation
of monosodium urate crystals aspirated from an affected joint or tophus and
if not, clinical characteristics recorded were sufficient to fulfill the prelim-
inary criteria for the classification of the acute arthritis of primary gout14.
The patients filled in a questionnaire regarding their disease, other
comorbidities, and medications. In addition, the patient’s full medical history
with special attention to CVD risk factors and medications was reviewed.
We assessed the effect of comorbidities such as heart disease, HTN, hyper-
cholesterolemia, DM, smoking habits, and testosterone levels on sexual
health assessed by SHIM. In addition, a thorough physical examination, as
well as recent laboratory studies including SU, lipid profile, white blood cell
count, glycosylated hemoglobin, CRP, and glomerular filtration rate (GFR)
were reviewed.
The dependent variable used was SHIM. Baseline variables were calcu-
lated as mean ± SD and median and interquartile range for continuous
variables, and as frequencies and percentages for categorical variables. We
compared the characteristics of men with gout versus men without gout and
their responses to the SHIM questionnaire using the chi-square test and
standard univariate statistics. Clinical characteristics of men in each category
of ED (none, mild to moderate, and severe) were compared for trend using
the Mantel–Haenszel chi-square test and ANOVA for trend on ranks for
categorical and continuous variables, respectively. Pearson chi-square test
and Mann–Whitney U tests were also reported for any ED (all categories)
versus no ED.
We collected variables that were pertinent to the question of ED. We
used a multivariable logistic regression analysis adjusting for whether a
patient had gout; age; comorbidities such as depression, diabetes, HTN,
elevated cholesterol, prostate disease, GFR, heart disease; and smoking
status to identify factors associated with the odds of getting ED.
RESULTS 
There were 201 men included in the study, all seen between
August 26, 2010, and May 13, 2013. Two patients declined
to participate in the study. Eighty-three patients had gout and
118 served as the control group. Baseline demographic and
clinical characteristics are shown in Table 1. Patients with
gout versus those without gout were comparable in terms of
total cholesterol and CRP levels as well as in the frequencies
of age, depression, peripheral vascular disease, prostate
disease, and alcoholism. However, patients with gout were
heavier and had more HTN and heart disease, as well as
higher SU and triglyceride levels, whereas there were more
active smokers among patients without gout. Testosterone
levels were checked in ≤ 5% of patients. Sixty-seven patients
with gout (80.7%) versus 76 patients without gout (64.4%)
had ≥ 2 underlying comorbidities.
The most common diseases in patients without gout
included rheumatoid arthritis (RA; n = 27), osteoarthritis 
(n = 27), psoriatic arthritis (n = 16), ankylosing spondylitis
(n = 10), systemic sclerosis (SSc; n = 9), polymyalgia
rheumatica (n = 6), low back pain (n = 5), systemic lupus
erythematosus (n = 4), granulomatosis with polyangiitis (n =
2), and other (n = 6).
A significantly greater proportion of patients with gout
(63, 76%) had ED versus patients without gout (60, 51%, 
p = 0.0003). A significantly greater proportion of patients
with gout (22, 26%) had severe ED versus patients without
gout (17, 15%, p = 0.04). Forty-one of patients with gout
(49%) versus 43 of the control group (37%) had
mild–moderate ED (p = 0.09).
The mean SHIM score of all patients was 16.81 with SD
7.93. Patients with gout had an average SHIM score of 14.4
and SD 8.11 versus 18.48 and SD 7.36 in patients without
gout (p < 0.0001).
Univariate and multivariate analysis were conducted in
associating ED with key risk factors such as gout, age,
depression, diabetes, fasting glucose, HTN, elevated choles-
terol level, prostate disease, GFR, and heart disease. The
unadjusted and adjusted OR and their 95% CI of ED on these
factors are listed in Table 2. The adjusted OR of ED on gout
was 2.92 with 95% CI 1.41–6.06, suggesting that men with
gout had almost 2-fold greater odds of getting ED than men
without gout. With the bootstrap hypothesis testing method,
we estimated the power of obtaining such a significant OR
was 79%15.
ED was present in 23 patients with gout (96%) versus 19
patients without gout (79%, p = 0.08) whose age was ≥ 65 
(n = 48). In patients with gout whose age was ≥ 65, severe
ED was present in 15 (60%) versus 8 patients without gout
(32%, p = 0.0002), and mild–moderate ED was present in 10
patients with gout (40%) whose age was ≥ 65 versus 14
patients without gout (56%, p = 0.26).
Fifty patients with gout (60%) were receiving
urate-lowering therapy (ULT) and/or colchicine. ULT
included febuxostat (40 mg daily, n = 13 and 80 mg daily, n
= 3), and daily doses of allopurinol 100 mg (n = 12), 200 mg
(n = 6), 300 mg (n = 8), 400 mg (n = 2), and 500 mg (n = 1).
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Thirty patients were taking chronic colchicine prophylaxis;
of those, 26 patients were treated with ULT and 4 were not.
Twenty-three patients with gout (27.7%) had visible tophi
on physical examination. Twenty patients with tophaceous
gout (87%) had ED versus 43 patients without tophi (71%, 
p = 0.12). Severe ED was reported in 6 patients with topha-
ceous gout (26%) versus 22 patients without tophi (37%, p =
0.44), and mild–moderate ED in 12 patients with tophaceous
gout (52%) versus 22 patients without tophi (37%, p = 0.22).
Duration of gout diagnosis prior to entering the study was
divided into 4 periods (< 5 yrs, 5 to < 10 yrs, 10 to < 20 yrs,
and ≥ 20 yrs). There were 33 patients with gout < 5 years: 21
(64%) with ED and 8 (38%) with severe ED. In the group
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Table 1. Patient demographics and clinical characteristics. Values are mean ± SD or n (%) unless otherwise
specified.
Characteristics Patients with Gout, n = 83Patients without Gout, n = 118 p
Age, yrs 56.67 ± 14.29 53.52 ± 13.70 0.12
Height, inches 68.41 ± 3.26 69.47 ± 3.23 0.03
Weight, lbs 219.62 ± 44.98 201.53 ± 39.72 0
Past smoker 26 (31.3) 26 (22.03) 0.45
Current smoker 52 (63.4) 85 (72.03) 0.29
BMI, kg/m2 33.07 ± 6.05 29.54 ± 5.25 0
Systolic BP, mmHg 127.93 ± 17.18 126.03 ± 14.32 0.4
Diastolic BP, mmHg 78.59 ± 10.91 77.31 ± 8.39 0.37
Total cholesterol 183.65 ± 45.04 175.87 ± 37.35 0.24
TG 204.31 ± 146.66 121.28 ± 71.29 0
HDL 43.71 ± 9.76 48.74 ±15.04 0.01
LDL 104.74 ± 35.15 102.17 ± 39.26 0.68
Serum urate, mg/dl 7.42 ± 2.20 6.05 ± 1.37 0
Fasting glucose 111.34 ± 36.24 99.35 ± 20.87 0.01
HbA1c 6.28 ± 1.23 5.87 ± 0.52 0.14
WBC 7.06 ± 2.26 9.17 ± 13.93 0.12
CRP 2.51 ± 3.39 2.89 ± 4.73 0.57
GFR, ml/min 65.50 ± 21.57 69.78 ± 23.21 0.2
Comorbidities
Diabetes mellitus 12 (14.5) 11 (9.32) 0.7
Hypertension 54 (65.1) 61 (51.69) 0.15
Heart disease 17 (20.5) 14 (11.86) 0.52
Blood vessel disease 2 (2.4) 5 (4.24) 0.7
Elevated cholesterol 43 (51.8) 36 (30.51) 0.06
Pelvic injuries 0 (0.0) 0 (0.00) 1
Low testosterone levels 6 (7.2) 7 (5.93) 0.92
Depression 8 (9.6) 10 (8.47) 0.93
Prostate disease 9 (10.8) 12 (10.17) 0.96
Prostatectomy 2 (2.4) 1 (0.85) 0.57
Tophi 23 (27.7) 2 (1.69) 0
CKD, GFR ml/min 0.52
No, > 60 48 (60) 75 (66)
Mild–moderate, 30–59 28 (35) 35 (31)
Severe, ≤ 29 4 (5) 3 (3)
p values are based on (1) Student t tests for binary variables when all cell counts are greater than 5, or Fisher’s
exact test otherwise; (2) chi-square tests for categorical variables with more than 3 levels when all cell counts are
greater than 5, or Monte Carlo simulations otherwise; (3) Student t tests for continuous variables. BMI: body mass
index; BP: blood pressure; TG: triglyceride; HDL: high-density lipoprotein; LDL: low-density lipoprotein; HbA1c:
glycosylated hemoglobin; WBC: white blood cell; CRP: C-reactive protein; GFR: glomerular filtration rate; CKD:
chronic kidney disease.
Table 2. Unadjusted and adjusted odds of patients getting ED.
Effect Unadjusted OR (95% CI) Adjusted OR (95% CI)
Gout 3.04 (1.64–5.66) 2.92 (1.41–6.06)
Age 1.06 (1.04–1.09) 1.06 (1.02–1.09)
Depression 2.38 (0.75–7.50) 1.76 (0.48–6.46)
Diabetes 1.92 (0.72–5.12) 1.15 (0.28–4.77)
Hypertension 2.09 (1.18–3.73) 1.32 (0.66–2.66)
Elevated cholesterol 2.09 (1.18–3.73) 1.24 (0.59–2.60)
Smoking 2.42 (1.31–4.47) 0.76 (0.18–3.17)
Prostate disease 2.97 (0.96–9.18) 1.21 (0.34–4.34)
GFR 0.99 (0.98–1.00) 1.01 (0.99–1.02)
Heart disease 3.91 (1.43–10.68) 2.16 (0.67–6.94)
ED: erectile dysfunction; GFR: glomerular filtration rate.
(18 patients) with gout 5 to < 10 years, 14 (78%) had ED and
8 (43%) had severe ED. There were 17 patients with gout 10
to < 20 years: 12 (71%) with ED and 3 (25%) with severe
ED. Finally, there were 11 patients with gout ≥ 20 years: 10
(91%) with ED and 5 (45%) with severe ED. Chi-square tests
showed that the proportions of ED and severe ED were not
significantly different among the 4 periods.
DISCUSSION
We found ED to be present in most men with gout (76%),
and the ED was frequently severe. We found the odds of
getting ED in patients with gout to be almost 2 times greater
than for men without gout. ED was significantly more
common in patients with gout with disease duration greater
than 20 years and patients with tophaceous gout. However,
ED was common in all patients with gout, not just those with
the highest gout burden. There was a statistically significant
association between gout and ED, even after adjustment for
age, HTN, obesity, and diabetes. The significance of our
findings is further highlighted by the control group being
composed of many patients with rheumatic diseases that have
an increased prevalence of ED, such as RA16 and SSc17,18.
We found ED to be common in our patients, those with gout
and the control group, and a major health problem. Previous
studies have shown RA and patients with SSc to have an
increased prevalence of ED16,17,18.
We used the SHIM, a widely used scale for screening and
diagnosis of ED and severity of ED in clinical practice and
research, to diagnose ED in our patients. Studies have used
the SHIM to diagnose ED in order to include patients with
ED in studies19 and to estimate the prevalence of ED in
patients with chronic diseases, as we did. The estimated
prevalence of ED was 68% for men with diabetes20, 70% for
men with chronic stable CAD21, 81% for men with SSc, and
48% for men with RA18. Researchers and patients found the
SHIM to be useful, quick, and inexpensive.
Our findings are important because ED, a common finding
in patients with gout, is an independent predictor of future
CV events. Endothelial dysfunction has an important role in
the pathophysiology of ED. The small diameter of the caver-
nosal arteries and the relatively high content of endothe -
lium-per-unit volume make the penile vascular bed a
sensitive marker for CVD22. Because the penile arteries are
small (1–2 mm) compared with the coronary arteries (3–4
mm), the same level of endothelial dysfunction and athero-
sclerosis may lead to a more significant reduction of blood
flow in the penile arteries compared with those of the
coronary arteries23.
Studies have examined the ability of ED to predict the risk
of future CV events (myocardial infarction, stroke, revascu-
larization) and mortality. In a metaanalysis of 14 prospective
cohort studies involving 92,757 men followed for a mean
period of 6 years, ED increased significantly and independ-
ently of traditional risk factors of CV events, mortality,
myocardial infarction, cerebrovascular events, and all-cause
mortality by 44%, 19%, 62%, 39%, and 25%, respectively24.
In men with known CVD, ED increased the risk of all-cause
mortality by 90%24. Of importance, the predictive ability of
ED is higher in younger patients with ED24.
It is, therefore, not surprising that patients with ED were
found to have an increased rate of concomitant silent CAD10.
In an angiographic study, about 1 in 5 men presenting with
ED had angiographically documented silent CAD25. These
findings underscore the need to identify patients with ED
needing further investigation for silent CAD26.
ED symptoms appear to precede coronary events by 2 to
3 years9,27.
The patient with ED, irrespective of whether he has estab-
lished CVD, is “reclassified” into a higher risk category for
future CV events27. More aggressive treatment is warranted of
CVD risk factors, commonly seen in our patients with gout, as
well as a close followup. The diagnosis of ED should prompt
an initial CV assessment based on the history and clinical
examination to define the baseline risk according to the
likelihood of silent or to the stage of clinically evident CAD27.
Hyperuricemia and inflammation may be independent risk
factors for ED in addition to the established ones. Uric acid
can induce endothelial dysfunction, oxidative stress, inflam-
mation, and microvascular disease, and this could provide a
link between uric acid and CVD and ED, as well as other
CAD risk factors28. Could hyperuricemia explain part of the
association between ED and gout? Would treatment of hyper-
uricemia improve erectile function? Studies should be
performed to determine the potential benefit of lowering SU
in patients with gout with ED in the presence or absence of
CAD. In addition, inflammation plays an important role in
ED11,12,28 and may be an important factor contributing to ED
in patients with gout. Sexual performance assessed by the
Erectile Function 5 (IIEF-5) score correlated inversely with
circulating levels of the endothelial prothrombotic and
inflammatory cytokines IL-1β and IL-69,10. Correction of
gouty inflammation may lead to improvement in erectile
function.
Previously, the Campaign Against Cancer and Heart
Disease study, using a community-based questionnaire of
2605 men, 256 (9.8%) conveying a history of gout, reported
in abstract form29 that ED, based on a polar (yes-no)
question, was significantly more common among participants
with gout as compared with participants without gout (39.8%
vs 28.8%, p < 0.001). Men with gout were significantly more
likely to have ED than men without gout, even after
adjustment for age. However, the association was not
observed after adjustment for obesity, HTN, and DM. The
study was hampered by several limitations. Many participants
were young and at a low CVD risk, and assessment of ED
was based on a polar (yes-no) question and not on a validated
questionnaire such as SHIM.
Our study has several strengths. Most importantly, these
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data were derived from a large clinic-based cohort and
include all patient ages. We used a validated outcome measure,
SHIM, to evaluate ED. There are, however, several limitations.
Cases of ED were ascertained through self-reported question-
naires. In addition, the SHIM does not assess sexual desire or
orgasm and does not diagnose the etiology of the ED, only its
presence and level of severity. Although every attempt was
made to include all male patients coming to the Rheumatology
clinic, inclusion was dependent on availability of NS and DR
to enroll patients during clinic time.
ED is present in most men with gout and is frequently
severe. Despite the importance of sexuality on the quality of
life, little attention has been paid to the effect of gout on
sexual function. A man with ED, even without cardiac
symptoms, is a cardiac patient until proven otherwise. A
diagnosis of ED should prompt an initial CV assessment
based on the history and clinical examination to define the
baseline risk according to the likelihood of silent or to the
stage of clinically evident CAD. Increasing awareness of ED
in patients with gout may lead to earlier medical attention,
treatment, and evaluation of possible silent CVD. Patients do
not volunteer sexual complaints; therefore, we propose that
all men with gout be routinely screened for ED.
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